GlassScriptPhysician profile
Christopher H Roberts
NPI 1609936293
$2,156.30
in general payments reported to CMS, 2019-2025
14 companies · $64.09 in 2025
The $64.09 reported for 2025 was less than what a typical Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) provider received nationally (typical 2025 total: $413).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $255 · 2020: $422 · 2021: $387 · 2022: $323 · 2023: $320 · 2024: $385 · 2025: $64.09.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $769.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $769.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $954.07 | 2019-2025 | Xifaxan |
| Abbvie INC. | $271.15 | 2019-2022 | |
| Novo Nordisk INC | $182.59 | 2020-2024 | Wegovy |
| Lilly USA, LLC | $162.52 | 2021-2024 | Mounjaro |
| Antares Pharma, INC. | $143.99 | 2021-2025 | Xyosted, Nocdurna, Tlando |
| Amgen INC. | $122.87 | 2019-2025 | Repatha, Otezla, Repatha |
| Radius Health, INC. | $108.71 | 2020-2024 | Tymlos |
| Exeltis, USA INC. | $56.26 | 2021-2024 | Slynd |
| Therapeuticsmd, INC. | $45.75 | 2020-2022 | |
| Acella Pharmaceuticals, LLC | $44.26 | 2023-2024 | NP Thyroid 60 |
| Astrazeneca Pharmaceuticals LP | $20.15 | 2024 | Breztri |
| Astellas Pharma US INC | $16.60 | 2020 | |
| Avion Pharmaceuticals | $13.98 | 2021 | |
| Dexcom, INC. | $13.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Roberts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.